


17th Annual
**T-Cell
Lymphoma
Forum**



January 29-31, 2026

WELCOME

Co-chairs:



Francine M. Foss, MD
Yale School of Medicine




Won Seog Kim, MD, PhD
Samsung Medical Center



Owen A. O'Connor, MD, PhD
University of Virginia

Geographic Representation





14 Countries

Australia	Korea (Republic of)
Belgium	Philippines
Brazil	Singapore
France	Switzerland
India	Ukraine
Italy	United Kingdom
Japan	United States

22 US States



Alabama	Illinois	New Jersey
Arizona	Kentucky	New York
California	Louisiana	Ohio
Colorado	Maryland	Pennsylvania
Connecticut	Massachusetts	Texas
Florida	Michigan	Utah
Georgia	Minnesota	Virginia
Indiana		

Representation by Degree



- APP or RN
- BA or BS
- Masters
- MD
- Other
- PharmD
- PhD

Forum Map



17th Annual
T-Cell Lymphoma Forum

MOBILE APP AND WIFI

Join us on our official conference app!

We're using CloudCME as our official Conference app. Click on Syllabus for all conference details!

How to join:

- Download CloudCME from the App Store on your device
- Open the app
- Enter organization code: UVA




iOS



Android

CloudCME



Connect to the Internet


Network: @Hyatt_Meetings

Password: 2026TCLF

Sponsored by **Kyowa Kirin**

TCellLymphForum.com

Sushi & Science Poster Reception




Friday at 5:10 – 6:30 pm
Sushi & Science
Poster Reception
In Ballroom D,E,F



Sponsored by
Secura Bio
Citius Oncology

17th Annual
T-Cell Lymphoma Forum

Scientific Posters Available Online




Poster #	Topics
1-2	Fellows' Forum Case: PTCL NOS (frontline) or ALK+ ALCL with IPI 4
3	Fellows' Forum Case: Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type
4-6	Fellows' Forum Case: T Follicular Helper (TFH) or Angioimmunoblastic T-cell Lymphoma (AITL)
7-8	Deep Dive Into CTCL
9-17	Insights Into the Pathology and Pathogenesis of T-Cell Malignancies
18-26	New Drugs for the Treatment of T-Cell Lymphoma
27-32	New Epidemiologic Data
33-38	New Insights Into Biological Targeting of T-Cell Malignancies (New Prospects)
39-44	Results from National/International Registries
45-51	Therapy and Results From Ongoing Clinical Trials



Scan Code to
View Posters Online
or visit:
[2026tclf.dryfta.com/
abstract-archive](https://2026tclf.dryfta.com/abstract-archive)

Forum Sponsors



Diamond Sponsors

SecuraBio 

Platinum Sponsors

 **CITIUS**
Oncology™

 **UVA Health**
UVA Cancer Center
An NCI-Designated Comprehensive Cancer Center

Gold Sponsors

 **CELLTRION**

 **KYOWA KIRIN**

Silver Sponsors

Therakos LLC

 **GC Cell**

 **NOUVEAU**
BIOSCIENCES

Bronze Sponsors

 **ELECTRA**
THERAPEUTICS

 **Bristol Myers Squibb®**

 **KYAN**
TECHNOLOGIES


 **Prescient**
Therapeutics

 **ACROTECH**
BIOPHARMA

 **clren bio**

 **ImmuneOncia**
Therapeutics Inc.

Event Sponsors



THURSDAY

Morning Break

Sponsor: UVA Cancer Center

Lunch

Sponsor: Celltrion

Afternoon Break

Sponsor: Nouveau BioSciences

FRIDAY

Breakfast: PETAL Consortium

Sponsor: Secura Bio

Morning Break

Sponsor: Prescient Therapeutics

Session 4: The Role of Adoptive Cellular and Immunotherapies for PTCL

Sponsor: GC Cell



Sushi & Science Poster Reception

Sponsors: Secura Bio & Citius Pharmaceuticals

17th Annual


T-Cell Lymphoma Forum

Visit the
Forum Website



TCellLymphForum.com

17th Annual
T-Cell Lymphoma Forum



SecuraBio 

Diamond Sponsor



UVA Comprehensive Cancer Center and Translational Orphan Blood Cancer Research Initiative

The UVA Comprehensive Cancer Center (UVACCC) is one of just 57 in the nation to hold that designation by the National Cancer Institute, and the first in Virginia. Our more than 200 researchers pursue discovery in support of cancer prevention, detection and treatment.



The UVA Comprehensive Cancer Center's Translational Orphan Blood Cancer Research Initiative (TOBCRI) pursues new treatments for blood cancers so rare they are designated "orphan" diseases and have historically received limited research scrutiny and funding. TOBCRI is an interdisciplinary, donor-supported and project-based effort that collaborates with partner institutions under the direction of two leading researchers: Owen A. O'Connor, MD, PhD, UVA's American Cancer Society Research Professor, who has invented and developed multiple blood cancer drugs, and Thomas Loughran, MD, PhD, UVACCC's Director and the discoverer of LGL leukemia.




UVA Cancer Center
An NCI-Designated Comprehensive
Cancer Center

Platinum Sponsor

FROM CITIUS ONCOLOGY


LYMPHIR Is Available For Use



 **LYMPHIR**[™]
(denileukin diftitox-cxd)
Injection 300 mcg

*Please see full Prescribing Information, including Boxed
Warning for Capillary Leak Syndrome at lymphirhcp.com.*

Platinum Sponsor




Pioneer: The World's First Antibody Biosimilar

Gold Sponsor of the 17th Annual T-Cell Lymphoma Forum
January 29 - 31, 2026



*Working to create a healthier tomorrow
where no patients are left untreated*

Gold Sponsor





PATIENTS DRIVE EVERYTHING WE DO.

We're focused on advancing new medicines that bring life-changing value in areas where the need remains greatest.

With our partners, we've advanced science and are taking bold steps to support patients facing some of the hardest-to-treat diseases.

kyowa KIRIN Translating Science Into Smiles

Gold Sponsor



Therakos LLC


VISIT OUR EXHIBIT BOOTH

Please see Full Prescribing Information,
including the Boxed Warning for Uvadex
(methoxsalen) Sterile Solution and the
THERAKOS CELLEX Photopheresis
System Operator's Manual by
scanning the QR code or
by calling 833-223-4327.



US-2500075 02/2025

Silver Sponsor



Navigating the Future

For Each and Every Patient


Every great breakthrough begins with a bold purpose.
At GC Cell, we lead innovation in cell & gene therapy
To accelerate tomorrow's cures, enhancing people's lives- for
every patient, for every tomorrow.

GC cell
Connecting science to hope, Connecting life to a better future.




Learn more at
www.gccell.com

Silver Sponsor



Silver Sponsor



ImmuneOncia
Therapeutics Inc.

Bronze Sponsor

Thank You to Our Sponsors

Diamond Sponsor



Secura Bio, Inc. is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians and their patients. Secura Bio was established in 2019 with a singular mission: to close the gap between innovative oncology therapies and the patients who need them most. For more information on Secura Bio, please visit www.securabio.com

Platinum Sponsors




Citius Oncology (NASDAQ: CTOR) is a start up biopharmaceutical company focused on commercializing innovative targeted oncology therapies. The company has launched LYMPHIR™ (denileukin diftiox-cxdl), for patients with stage 1-3, relapsed or refractory cutaneous T-cell lymphoma (CTCL) in the US. Please contact us if you have any questions or visit www.lymphir.com



UVA Cancer Center
An NCI-Designated Comprehensive Cancer Center

The UVA Comprehensive Cancer Center is one of just 57 in the nation to hold that designation by the National Cancer Institute, and the first in Virginia. Our more than 250 researchers pursue discovery in support of cancer prevention, detection and treatment. UVACCC's work directly supports patients seen by UVA Health clinicians and individuals who live in the UVACCC catchment area through outreach partnerships. UVACCC offers robust education and career development activities to participants ranging from elementary school students to junior faculty to train the next generation of cancer researchers and clinicians. UVACCC strives to reduce the burden of cancer for all. Additionally, affiliated research initiatives pursue discovery related to rare or "orphan" cancers, and novel treatment methods. UVACCC is proud to support the 17th Annual T-cell Lymphoma Forum in San Diego.

17th Annual
T-Cell Lymphoma Forum



Thank You to Our Sponsors

Gold Sponsors



Celltrion is a global biopharmaceutical leader dedicated to enhancing patient well-being. As the pioneer that launched the world's first monoclonal antibody biosimilar, we boast an annual production capacity of 250,000L, making us Korea's largest manufacturer and exporter in the sector. For over two decades, we have expanded treatment accessibility through advanced, affordable healthcare solutions. Moving forward, we are elevating our impact by diversifying our portfolio into innovative new drugs, including multi-specific antibodies and antibody-drug conjugates (ADCs), to create a healthier future for everyone.



Kyowa Kirin is a Japan-based global specialty pharmaceutical company focused on next generation antibodies and cell and gene therapies to help patients diagnosed with bone and mineral, intractable hematological diseases/hemato oncology, and rare diseases. We have a shared commitment to our values and Kabegoe principles, to sustainable growth, and to translating science into smile across the globe. www.kkna.kyowakirin.com.

Silver Sponsors



Therakos LLC specializes in photopheresis technology and has the only FDA approved extracorporeal photopheresis treatment in the US. Please see full Prescribing Information, including the BOXED WARNING for UVADEX (methoxsalen) Sterile Solution at www.therakos.com/pi and see the THERAKOS Photopheresis System Operator's Manual. To learn more about our product visit www.therakos.com




GC Cell stands at the forefront of cell therapy innovation with fully-integrated capability from research to commercialization. Offering customized solutions tailored to partners' needs, We provide end-to-end full value chain CDMO and bio logistics service. Our mission is to fast-track the innovation in cell and gene therapies, aiming to enhance the clinical outcomes of each and every patient, shaping the future of healthcare.



Nouveau Biosciences brings together leaders in business, science, and regulation to advance oncology drug discovery and development. We pioneer technologies enabling rapid creation of targeted cancer therapies. With a clinic-ready lead asset and scalable, IP-protected platform, we generate de-risked drug candidates with strong potential for swift market entry to patients.

17th Annual
T-Cell Lymphoma Forum



Thank You to Our Sponsors

Bronze Sponsors



17th Annual
T-Cell Lymphoma Forum

